SCHEMBL5831422

SCHEMBL5831422

COP(=O)(CCCCc1ccccc1)OC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
MAPT P10636 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
CETP P11597 4/20 0.42
S1PR2 O95136 1/20 0.41
S1PR4 O95977 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
HDAC1 Q13547 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HDAC3 O15379 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA1A P35348 1/20 0.41
HDAC4 P56524 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27991959 0.86 TSHR (0.50) TSHRMAPTRXFP1CETPS1PR2
SCHEMBL10936592 0.86 CETP (0.46) TSHRMAPTRXFP1CETPMAPK1
SCHEMBL8949633 0.84 SIGMAR1 (0.50) TSHRMAPTRXFP1CETPS1PR2
SCHEMBL7379078 0.83 TSHR (0.53) TSHRMAPTRXFP1CETPS1PR2
SCHEMBL27991950 0.81 TSHR (0.47) TSHRCETPS1PR2S1PR4S1PR1
SCHEMBL3743712 0.80 ABCB11 (0.37) TSHRCETPS1PR2S1PR4S1PR1
SCHEMBL3421210 0.76 CETP (0.38) CETPSMN1; SMN2
SCHEMBL3975163 0.75 MAPT (0.51) MAPTRXFP1HDAC1HDAC3MAPK1
SCHEMBL5831419 0.75 LMNA (0.47) TSHRMAPTRXFP1CETPS1PR2
SCHEMBL11509944 0.75 CETP (0.49) TSHRCETPHDAC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078532-B2 Process for manufacture of fosinopril sodium LUPIN LABORATORIES LIMITED (IN) 2006-07-18 US disclosed
US-20040225127-A1 Process for manufacture of fosinopril sodium LUPIN LABORATORIES LIMITED (IN) 2004-11-11 US disclosed
US-5739123-A ANGIOTENSIN CONVERTING ENZYME INHIBITOR TREATING CARDIOVASCULAR DISEASES ZAMBON GROUP S.P.A. (IT) 1998-04-14 US disclosed
EP-0766687-A1 PHOSPHINIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY ZAMBON GROUP S.p.A. (IT) 1997-04-09 EP disclosed
WO-1995035302-A1 PHOSPHINIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225127-A1 Process for manufacture of fosinopril sodium FOS, FOSB, AGT TSHR 3065/4885MAPT 2302/4885RXFP1 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.